Sold Secure Diamond tested smart security sets a new benchmark for the U.S. bicycle marketSHARON, MA — March 11, 2026 — Todson, Inc., a leading distributor in the U.S. cycling industry, today ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...
Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally ...
Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership ...
Cycling Weekly on MSN
The world’s safest bicycle helmet? Meet the PIKIO Si
How do you make the safest possible bicycle helmet? Overall shape plays a big part, as does foam density and placement, but ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today ...
“Bicycle made significant progress in 2025 and looks forward to achieving its 2026 priorities. We believe our evolved leadership team, in collaboration with our expert board of directors and advisors, ...
Phase 2/3 Duravelo-2 pivotal trial evaluating zelenectide pevedotin (zelenectide) plus pembrolizumab in metastatic urothelial cancer (mUC) successfully identifies 6mg/m2 zelenectide two weeks on, one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results